<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053208</url>
  </required_header>
  <id_info>
    <org_study_id>149-07</org_study_id>
    <nct_id>NCT01053208</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fasting Condition</brief_title>
  <official_title>Open Label,Balanced,Randomized,Two-treatment,Two-sequence,Two Period,Single-dose,Crossover Oral Bioequivalence Study of Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets of Dr.Reddy's and Advil®PM of Wyeth in Normal,Healthy,Adult,Human Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the single-dose oral bioequivalence study of Ibuprofen and Diphenhydramine
      citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories Limited, India and Advil® PM, of
      Wyeth consumer health care, USA, in normal, healthy, adult, human subjects under fasting
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description : The study was conducted as an Open label, balanced, randomized,
      two-treatment, two-sequence, two period,single-dose, crossover oral bioequivalence study of
      Ibuprofen and Diphenhydramine citrate 200 mg/38 mg caplets of Dr. Reddy's Laboratories
      Limited, India and Advil@PM, of Wyeth Consumer Healthcare, USA., in normal, healthy, adult,
      human subjects under fasting conditions. A total number of forty (40) subjects were enrolled
      in the study and all the subjects completed both the periods of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence study of Dr. Reddys Laboratories Limited, Ibuprofen and Diphenhydramine Citrate Caplets under fasting condition</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ibuprofen and Diphenhydramine Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advil PM 200 mg/38 mg Tablets of Wyeth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen and Diphenhydramine Citrate</intervention_name>
    <description>Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets</description>
    <arm_group_label>Ibuprofen and Diphenhydramine Citrate</arm_group_label>
    <arm_group_label>Advil</arm_group_label>
    <other_name>Advil PM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy human subjects aged between 18 and 45 years (including both).

          -  Subjects with a BMI between 18.5 - 24.9 Kg/m2 (including both) but body weight not
             less than 45 Kgs.

          -  Subjects with normal health as determined by personal medical history, clinical
             examination, and laboratory examinations including serological tests.

          -  Subjects having normal 12 lead electrocardiogram (ECG)

          -  Subjects having normal chest X-Ray (P/A view).

          -  Subjects able to communicate effectively.

          -  Subjects willing to give written informed consent and adhere to all the requirements
             of this protocol.

          -  Female subjects who are postmenopausal or surgically sterile.

          -  Female subjects practicing an acceptable method of birth control for the duration of
             the study as judged by the investigator(s), such as condoms, foams, jellies,
             diaphragm,intrauterine device (IUD) or abstinence.

        Exclusion Criteria:

          -  Subjects having contraindications or hypersensitivity to Ibuprofen Diphenhydramine
             citrate or related group of drugs.

          -  History or presence of any medical conditions or disease according to the opinion of
             the physician.

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological, neurological or
             psychiatric disease or disorder.

          -  History or presence of significant alcoholism or drug abuse in the past one year.

          -  History or presence of significant smoking (more than 10 cigarettes or bidis/day or
             consumption of tobacco products).

          -  Difficulty with donating blood.

          -  Difficulty in swallowing solids like tablets or capsules.

          -  Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.

          -  Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.

          -  Pulse rate less than 50 beats/minute or more than 100 beats/minute.

          -  Use of any prescribed medication during last two weeks or OTC medicinal products
             during the last one week preceding the first dosing.

          -  Major illness during 3 months before screening.

          -  Participation in a drug research study within past 3 months.

          -  Donation of blood in the past 3 months before screening.

          -  Female subjects demonstrating a positive pregnancy screen.

          -  Female subjects who are currently breast-feeding.

          -  Female subjects with child bearing potential using prohibited contraceptive method
             (Oral, Injectable or Implantable hormonal agents).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N. Netaji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GVK Biosciences Pvt. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GVK Biosciences Pvt. Ltd</name>
      <address>
        <city>Amirpet</city>
        <state>Hyderabad</state>
        <zip>500 038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>January 20, 2010</last_update_submitted>
  <last_update_submitted_qc>January 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director Clinical Pharmacology &amp; Pharmacokinetics</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence,Ibuprofen Diphenhydramine Citrate,Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

